...
首页> 外文期刊>Annals of surgical oncology >Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
【24h】

Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

机译:围手术期血清CA 19-9水平对可切除胰腺癌患者的预后影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Pancreatic cancer is one of the most deadly cancers, and serum carbohydrate antigen 19-9 (CA19-9) level has been reported to be a useful prognostic marker in pancreatic cancer. The purpose of this study was to determine which prognostic factor (preoperative or postoperative serum CA19-9 level) is more useful. METHODS: Pre- and postoperative serum CA19-9 levels were measured in 109 patients who underwent surgical resection for pancreatic cancer between 1998 and 2009, and their relationships to clinicopathological factors and overall survival were analyzed with univariate and multivariate methods. RESULTS: In univariate analysis, tumor location (P = 0.019), postoperative adjuvant chemotherapy (P < 0.001), residual tumor factor status (P < 0.001), UICC pT stage (P = 0.004), lymph node metastasis (P = 0.015), and UICC final stage (P = 0.015) were significantly associated with overall survival. Differences in overall survival were significant between groups divided on the basis of four postoperative CA19-9 cutoff values (37, 100, 200, and 500 U/ml) but not significant between groups divided on the basis of the same four preoperative CA19-9 cutoff values. Pre- to postoperative increase in CA19-9 level also was significantly associated with poor prognosis. In multivariate analysis, postoperative adjuvant chemotherapy (hazard ratio, 1.59; P = 0.004) and postoperative CA19-9 cutoff value of 37 U/ml (HR, 1.64; P = 0.004) remained independent predictors of prognosis. CONCLUSIONS: Postoperative CA19-9 level is a better prognostic factor than preoperative CA19-9 level, and curative surgery for resectable pancreatic cancer should be tried regardless of the preoperative CA19-9 level.
机译:背景:胰腺癌是最致命的癌症之一,据报道血清碳水化合物抗原19-9(CA19-9)水平是胰腺癌的有用预后标志物。这项研究的目的是确定哪种预后因素(术前或术后血清CA19-9水平)更有用。方法:测量1998年至2009年间109例胰腺癌手术切除患者的术前和术后血清CA19-9水平,并采用单因素和多因素方法分析其与临床病理因素和总生存率的关系。结果:在单因素分析中,肿瘤位置(P = 0.019),术后辅助化疗(P <0.001),残余肿瘤因子状态(P <0.001),UICC pT分期(P = 0.004),淋巴结转移(P = 0.015)和UICC最终阶段(P = 0.015)与总体生存率显着相关。根据四个术后CA19-9临界值(37、100、200和500 U / ml)划分的各组之间的总生存率差异显着,而根据相同的四个术前CA19-9划分的各组之间的总生存率差异不显着截止值。术前CA19-9水平升高也与预后不良相关。在多变量分析中,术后辅助化疗(危险​​比,1.59; P = 0.004)和术后CA19-9临界值为37 U / ml(HR,1.64; P = 0.004)仍然是预后的独立预测指标。结论:术后CA19-9水平较术前CA19-9水平为更好的预后因素,无论术前CA19-9水平如何,均应尝试治愈性可切除胰腺癌的手术治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号